Silvercrest Asset Management Group LLC Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Silvercrest Asset Management Group LLC trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 39.1% in the 1st quarter, Holdings Channel reports. The firm owned 94,635 shares of the medical research company’s stock after selling 60,708 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Natera were worth $8,655,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Natera by 28.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after purchasing an additional 159,993 shares during the last quarter. Cerity Partners LLC increased its holdings in Natera by 1,043.3% during the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after buying an additional 82,514 shares during the last quarter. WCM Investment Management LLC increased its holdings in Natera by 101.2% during the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after buying an additional 73,419 shares during the last quarter. Thematics Asset Management increased its holdings in Natera by 3.1% during the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock valued at $5,652,000 after buying an additional 2,738 shares during the last quarter. Finally, Crestline Management LP increased its holdings in Natera by 16.0% during the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock valued at $4,076,000 after buying an additional 8,997 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Natera news, insider Daniel Rabinowitz sold 30,000 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $104.59, for a total transaction of $3,137,700.00. Following the completion of the transaction, the insider now owns 204,495 shares in the company, valued at $21,388,132.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Steven Leonard Chapman sold 37,500 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.10, for a total value of $4,053,750.00. Following the sale, the chief executive officer now owns 213,351 shares of the company’s stock, valued at $23,063,243.10. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Daniel Rabinowitz sold 30,000 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $104.59, for a total transaction of $3,137,700.00. Following the completion of the sale, the insider now directly owns 204,495 shares in the company, valued at approximately $21,388,132.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,142 shares of company stock worth $11,843,319. 7.60% of the stock is owned by insiders.

Analyst Ratings Changes

NTRA has been the subject of a number of research reports. Craig Hallum initiated coverage on shares of Natera in a report on Monday, April 8th. They set a “buy” rating and a $117.00 target price for the company. The Goldman Sachs Group upped their target price on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, April 15th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a report on Friday, May 17th. TD Cowen upped their target price on shares of Natera from $123.00 to $137.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Jefferies Financial Group began coverage on shares of Natera in a research report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price target for the company. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $101.19.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $97.75 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The firm has a fifty day moving average price of $108.80 and a 200 day moving average price of $93.25. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $117.23. The firm has a market cap of $12.00 billion, a price-to-earnings ratio of -31.33 and a beta of 1.48.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The firm had revenue of $367.70 million during the quarter, compared to analyst estimates of $316.31 million. During the same quarter in the prior year, the business earned ($1.23) earnings per share. Natera’s revenue for the quarter was up 52.1% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.